Please use this identifier to cite or link to this item: http://www.arca.fiocruz.br/handle/icict/12641
Title: Predictive value of transforming growth factor-b1in Chagas disease: towards a biomarker surrogate of clinical outcome
Authors: Saraiva, Roberto M.
Waghabi, Mariana C.
Vilela, Maíra F.
Madeira, Fabiana S.
Silva, Gilberto M Sperandio da
Xavier, Sérgio S.
Feige, Jean J.
Moreno, Alejandro M. Hasslocher
Araujo-Jorge, Tania C.
Affilliation: Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Institut National de la Santé et de la Recherché Médicale. Grenoble, France.
Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Rio de Janeiro, RJ, Brasil.
Abstract: Background: Transforming growth factor-b1 (TGF-b1) may be implicated in the development of Chagas heart disease. However, the clinical value of TGF-b1 measurement is yet to be determined. Methods: We retrospectively analyzed the outcome of 54 Chagas disease patients without heart failure and with left ventricular (LV) ejection fraction .45% whose TGF-b1 serum values were determined between January 1998 and December 1999. Primary end point was all-cause mortality and secondary end point was the combination of all-cause mortality or hospitalization due to worsening heart failure or cardiac arrhythmias. Results: TGF-b1 was independently associated with the occurrence of the primary and secondary end points. The optimal cutoff for TGF-b1 to identify the primary end point was 12.9 ng/ml (area under the curve ¼ 0.82, p ¼ 0.004, sensitivity 100%, and specificity 57%) and to identify the secondary end point was 30.8 ng/ml (area under the curve ¼ 0.72, p ¼ 0.03, sensitivity 60%, and specificity 86%). LV ejection fraction and LV end-diastolic diameter were also independent predictors of the primary and secondary endpoints, respectively. Conclusion: The described association between TGF-b1 and clinical outcome provides evidence towards the clinical value of TGF-b1 in Chagas disease.
Keywords: Chagas disease
Heart failure
Transforming growth factor-b1
Echocardiography
Prognosis
DeCS: Doença de Chagas
Insuficiência Cardíaca
Ecocardiografia
Prognóstico
Issue Date: 2013
Publisher: Oxford University Press
Citation: SARAIVA, Roberto M. et al. Predictive value of transforming growth factor-b1in Chagas disease: towards a biomarker surrogate of clinical outcome. Trans R Soc Trop Med Hyg, v.107, p.518 –525, 2013.
DOI: 10.1093/trstmh/trt050
ISSN: 0035-9203
Copyright: restricted access
Appears in Collections:IOC - Artigos de Periódicos

Files in This Item:
File Description SizeFormat 
mariana_waghabi_etal_IOC_2013.pdf212.66 kBAdobe PDF    Request a copy


FacebookTwitterDeliciousLinkedInGoogle BookmarksBibTex Format mendeley Endnote DiggMySpace

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.